Drugs / Propevirine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05490082 Comparator | Mar 2022 → Mar 2023 | urinary bladder disorder | Mansoura University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Propevirine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05490082 ↗ |
| Route | Oral | “15 mg PO twice daily” NCT05490082 ↗ |